Identifying Antidepressant Effects of Brain-Derived Neurotrophic Factor and IDO1 in the Mouse Model Based on RNA-Seq Data

Identifying Antidepressant Effects of Brain-Derived Neurotrophic Factor and IDO1 in the Mouse Model Based on RNA-Seq Data

Deletion of brain-derived neurotrophic factor (BDNF) and upregulation of indoleamine 2,3-dioxygenase 1 (IDO1) are associated with depression severity in animals. The neurotransmitter hypothesis of depression at the transcriptomic level can be tested using BDNF- and IDO1-knockout mouse models and RNA...

Full description

Bibliographic Details
Main Authors:	Jing Ren, Chenyang Li, Songren Wei, Yanjun He, Peng Huang, Jiangping Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Genetics
Subjects:	depression RNA-seq pathway enrichment analysis protein–protein interaction (PPI) network brain-derived neurotrophic factor (BDNF) indoleamine 2,3-dioxygenase 1 (IDO1)
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.890961/full

Similar Items

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
by: Chiara Suvieri, et al.
Published: (2024-11-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
by: Eleonora Panfili, et al.
Published: (2023-04-01)

On the nonredundant roles of TDO2 and IDO1
by: Paolo ePuccetti
Published: (2014-10-01)

IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)

IDO/kynurenine pathway in cancer: possible therapeutic approaches
by: Eslam E. Abd El-Fattah
Published: (2022-08-01)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
by: Takefumi Komiya, et al.
Published: (2018-10-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
by: Chuan Zhou, et al.
Published: (2020-03-01)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T Cells in Mammals
by: Ursula eGrohmann, et al.
Published: (2015-02-01)

Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity
by: Mincheol Kwon, et al.
Published: (2019-01-01)

Targeting the IDO1 pathway in cancer: from bench to bedside
by: Ming Liu, et al.
Published: (2018-08-01)

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies
by: Jiang K, et al.
Published: (2024-08-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01)

Systemic tryptophan homeostasis
by: Simon Klaessens, et al.
Published: (2022-09-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)

Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors
by: Marta Serafini, et al.
Published: (2019-05-01)

IDO1 modulates pain sensitivity and comorbid anxiety in chronic migraine through microglial activation and synaptic pruning
by: Jiao Hu, et al.
Published: (2025-02-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
by: Qian Huang, et al.
Published: (2018-04-01)

DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota
by: Li-Ping Zhao, et al.
Published: (2023-01-01)

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer
by: Yinnan Meng, et al.
Published: (2021-01-01)

1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
by: Huihan Ma, et al.
Published: (2020-09-01)

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020-09-01)

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
by: Yu Yao, et al.
Published: (2021-02-01)

Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
by: Irina Banzola, et al.
Published: (2018-05-01)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
by: Linfang Wu, et al.
Published: (2022-08-01)

Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance
by: Delia Hoffmann, et al.
Published: (2020-12-01)

The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma
by: E Orecchini, et al.
Published: (2023-12-01)

Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation
by: Nourhan M. Aboomar, et al.
Published: (2024-04-01)

Nattokinase mitigated dextran sulfate sodium-induced chronic colitis by regulating microbiota and suppressing tryptophan metabolism via inhibiting IDO-1
by: Lvqi Zhou, et al.
Published: (2020-12-01)

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources
by: Ying Tan, et al.
Published: (2022-11-01)

Tumor Microenvironment‐Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic Immunosuppression
by: Mengna Wang, et al.
Published: (2025-02-01)

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
by: Mee-seon Kim, et al.
Published: (2020-05-01)

Significance of Indoleamine 2,3-Dioxygenase Expression in the Immunological Response of Kidney Graft Recipients
by: Krzysztof Wiśnicki, et al.
Published: (2022-09-01)

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
by: Adaobi Amobi-McCloud, et al.
Published: (2021-04-01)

Progesterone decreased indoleamine 2,3-dioxygenase 1(IDO1) expression in early pregnancy chorionic villi and decidua
by: Minyan Yang, et al.
Published: (2021-04-01)

Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue–Focus on RAGE and IDO1
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)

Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
by: Xi Xu, et al.
Published: (2019-01-01)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis
by: Lisa A. Wetzel, et al.
Published: (2020-08-01)